Zhenghao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenghao Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Chunguang Yang
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications - Ke Chen
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publications - Lilong Liu
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publications - Yang Li
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
2 shared publications - Zhen Li
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications Chengzhang Zhang
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in npj Digital Medicine
Multicenter benchmarking of large language models for bladder cancer management recommendations from mpMRI reports
- 13 November 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessMulticenter benchmarking of large language models for bladder cancer management recommendations from mpMRI reports
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Nuclear Factor Erythroid 2-Related Factor 2 Negatively Regulates Docetaxel-Induced Ferroptosis in Castration-Resistant Prostate Cancer Cells
Ke C, et al. World J Mens Health. 2026 ;44:e30. https://doi.org/10.5534/wjmh.250299
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessNuclear Factor Erythroid 2-Related Factor 2 Negatively Regulates Docetaxel-Induced Ferroptosis in Castration-Resistant Prostate Cancer Cells
Ke C, et al. World J Mens Health. 2026 ;44:e30. https://doi.org/10.5534/wjmh.250299
- Open Access
- 10 September 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.
- 10 September 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessAn evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.
- Open Access
- 31 March 2024
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 28 (1) , 33-43
Prediction of Prostate Cancer Risk Stratification Based on A Nonlinear Transformation Stacking Learning Strategy
Purpose: Prostate cancer (PCa) is an epithelial malignancy that originates in the prostate gland and is generally categorized into low, intermediate, and high-risk groups. The primary diagnostic indicator for PCa is the measurement of serum prostate-specific antigen (PSA) values. However, reliance on PSA levels can result in false positives, leading to unnecessary biopsies and an increased risk of invasive injuries. Therefore, it is imperative to develop an efficient and accurate method for PCa risk stratification. Many recent studies on PCa risk stratification based on clinical data have employed a binary classification, distinguishing between low to intermediate and high risk. In this paper, we propose a novel machine learning (ML) approach utilizing a stacking learning strategy for predicting the tripartite risk stratification of PCa.Methods: Clinical records, featuring attributes selected using the lasso method, were utilized with 5 ML classifiers. The outputs of these classifiers underwent transformation by various nonlinear transformers and were then concatenated with the lasso-selected features, resulting in a set of new features. A stacking learning strategy, integrating different ML classifiers, was developed based on these new features.Results: Our proposed approach demonstrated superior performance, achieving an accuracy of 0.83 and an area under the receiver operating characteristic curve value of 0.88 in a dataset comprising 197 PCa patients with 42 clinical characteristics.Conclusions: This study aimed to improve clinicians’ ability to rapidly assess PCa risk stratification while reducing the burden on patients. This was achieved by using artificial intelligence-related technologies as an auxiliary method for diagnosing PCa.
- 31 March 2024
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 28 (1) , 33-43
Open AccessPrediction of Prostate Cancer Risk Stratification Based on A Nonlinear Transformation Stacking Learning Strategy
Purpose: Prostate cancer (PCa) is an epithelial malignancy that originates in the prostate gland and is generally categorized into low, intermediate, and high-risk groups. The primary diagnostic indicator for PCa is the measurement of serum prostate-specific antigen (PSA) values. However, reliance on PSA levels can result in false positives, leading to unnecessary biopsies and an increased risk of invasive injuries. Therefore, it is imperative to develop an efficient and accurate method for PCa risk stratification. Many recent studies on PCa risk stratification based on clinical data have employed a binary classification, distinguishing between low to intermediate and high risk. In this paper, we propose a novel machine learning (ML) approach utilizing a stacking learning strategy for predicting the tripartite risk stratification of PCa.Methods: Clinical records, featuring attributes selected using the lasso method, were utilized with 5 ML classifiers. The outputs of these classifiers underwent transformation by various nonlinear transformers and were then concatenated with the lasso-selected features, resulting in a set of new features. A stacking learning strategy, integrating different ML classifiers, was developed based on these new features.Results: Our proposed approach demonstrated superior performance, achieving an accuracy of 0.83 and an area under the receiver operating characteristic curve value of 0.88 in a dataset comprising 197 PCa patients with 42 clinical characteristics.Conclusions: This study aimed to improve clinicians’ ability to rapidly assess PCa risk stratification while reducing the burden on patients. This was achieved by using artificial intelligence-related technologies as an auxiliary method for diagnosing PCa.